A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
09 2021
Historique:
received: 17 02 2021
revised: 22 03 2021
accepted: 23 03 2021
pubmed: 4 5 2021
medline: 21 1 2022
entrez: 3 5 2021
Statut: ppublish

Résumé

In this narrative review, key developments in epidemiologic and clinical outcomes-based research from eminent historical data sources over the past quarter century are summarized. We then describe the rise of secondary and administrative datasets (AD), summarizing the predominant types of available secondary datasets for contemporary research and describe the benefits and inherent limitations in working with secondary data. We review the methodological advances that permit researchers to capitalize on the full capability of secondary data while also addressing the limitations inherent in utilizing these data for the purposes of epidemiologic and outcomes research. Finally, we present candidate strategies to perpetuate this momentum towards optimizing the development of clinical research infrastructure that harnesses the full potential of the ADs to further clinical and epidemiological research, advancing data analysis, and address the many unanswered questions that remain.

Identifiants

pubmed: 33934967
pii: S1078-1439(21)00129-0
doi: 10.1016/j.urolonc.2021.03.019
pii:
doi:

Types de publication

Historical Article Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

595-601

Subventions

Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Sarah P Psutka (SP)

Department of Urology, University of Washington, Seattle, WA. Electronic address: spsutka@uw.edu.

Eric A Singer (EA)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

John Gore (J)

Department of Urology, University of Washington, Seattle, WA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH